http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Arcutis Biotherapeutics Inc. (ARQT) Highlights New Positive Data from Phase 2 Studies of ARQ-151 (Topical Roflumilast Cream)
-
Arcutis Biotherapeutics Presents New Positive Data from Phase 2 Studies of ARQ-151 (Topical Roflumilast Cream) in Chronic Plaque Psoriasis and Atopic Dermatitis
-
Arcutis Biotherapeutics to Present New Data from ARQ-151 (Topical Roflumilast Cream) Clinical Program at Three Global Dermatology Conferences
-
Arcutis Completes Enrollment in Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema
-
Arcutis Biotherapeutics Inc. (ARQT) Reports Positive Topline Data from Phase 2 Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis
-
Arcutis Announces Positive Topline Data from Phase 2 Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis
-
Arcutis Biotherapeutics Inc. (ARQT) Reports Complete Enrollment in DERMIS-1 & DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 as Potential Treatment for Plaque Psoriasis
-
Arcutis Completes Enrollment in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis
-
Arcutis to Present at the Cantor Fitzgerald Global Healthcare Conference 2020
-
Arcutis Biotherapeutics Inc. (ARQT) to Advance ARQ-151 (Topical Roflumilast Cream) into Phase 3 Trials Following End-of-Phase 2 Meeting with FDA
-
Arcutis Biotherapeutics to Accelerate ARQ-151 (Topical Roflumilast Cream) into Phase 3 Trials for the Treatment of Atopic Dermatitis Following End-of-Phase 2 Meeting with FDA
-
Arcutis Announces Second Quarter 2020 Financial Results and Provides Business Update
-
Arcutis to Present at the Wedbush PacGrow Healthcare Conference
-
Bethany Dudek Joins Arcutis as Vice President of Quality
-
Arcutis Biotherapeutics Inc. (ARQT) Announces Publication of Data from Positive Phase 1/2a Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream)
-
The Journal of Drugs in Dermatology Publishes Results from Positive Phase 1/2a Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque Psoriasis
-
Arcutis Bio (ARQT) Says Preliminary Data from Long-Term Safety Study Support Chronic Use of ARQ-151 as Potential Treatment for Plaque Psoriasis
-
Preliminary Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis
-
Arcutis Appoints Patrick Burnett, M.D., Ph.D., FAAD, as Chief Medical Officer
-
Arcutis Biotherapeutics Inc. (ARQT) Reports Last Patient Enrollment in Phase 2b Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as Potential Treatment for Scalp Psoriasis
-
Arcutis Enrolls Last Patient in Phase 2b Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp Psoriasis
-
Arcutis Biotherapeutics Inc. (ARQT) Reports Publication of Results for Positive Phase 2b Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for Treatment of Chronic Plaque Psoriasis
-
The New England Journal of Medicine Publishes Results from Positive Phase 2b Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque Psoriasis
-
The New England Journal of Medicine Publishes Results from Positive Phase 2b Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque Psoriasis
-
Arcutis Initiates Patient Enrollment in the Phase 2b Portion of the Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema

